Nigeria Receives Breakthrough HIV Prevention Injection Lenacapavir
Nigeria has taken a monumental step forward in its decades-long battle against HIV with the official introduction of Lenacapavir, a revolutionary long-acting injection for HIV prevention. Health Minister Ali Pate confirmed the approval of this twice-yearly administered drug, marking what experts describe as a potential turning point in public health strategy.
Transforming Prevention Through Simplicity
Unlike traditional daily PrEP pills that require consistent adherence, Lenacapavir offers protection through injections administered just every six months. This fundamental shift addresses one of the biggest challenges in HIV prevention: maintaining daily medication routines. For individuals facing stigma, limited healthcare access, or unstable living conditions, this simplified approach could dramatically improve protection rates.
Dr. Adebobola Bashorun, National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme, emphasized the significance of this development: "By expanding prevention options and strengthening service delivery, we are taking decisive steps to reduce new HIV infections and improve health outcomes across the country."
Addressing Nigeria's HIV Burden
With approximately 1.9 million people living with HIV and thousands of new infections occurring annually, Nigeria carries one of the world's heaviest HIV burdens. The arrival of Lenacapavir comes at a critical moment, following recent disruptions to international HIV funding that have strained prevention programs.
The injection works as pre-exposure prophylaxis (PrEP) for HIV-negative individuals at risk of contracting the virus. Once administered, it continuously blocks HIV replication in the body if exposure occurs, providing six months of protection with each dose.
Affordable Access Through Global Partnership
Perhaps most significantly, Lenacapavir will be available at an estimated annual cost of $40 (approximately ₦58,000) per person through voluntary licensing agreements with generic manufacturers. This pricing structure, facilitated by Global Fund support, makes the breakthrough treatment accessible across Nigeria and 119 other low- and middle-income countries.
Health authorities are now collaborating with partners and stakeholders to ensure the safe, effective rollout of Lenacapavir across Nigeria's healthcare system. The injection will be integrated into existing HIV prevention programs, with particular focus on populations at higher risk of infection.
As Nigeria implements this new prevention tool, health experts anticipate it could help close long-standing gaps in HIV protection and potentially reduce new infection rates. For a country that has fought HIV for generations, this small vial represents more than just medicine—it symbolizes a new era where staying protected doesn't depend on remembering daily pills.
